(1) Newly diagnosed, advanced (FIGO stage III–IV), high-grade ovarian cancer(2) Partial or complete clinical response to platinum-based chemotherapy.(3) Mutation in BRCA1, BRCA2, or both (BRCA1/2). Here, BRCA1 is linked to ovarian cancer.